![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
V Heinemann, YZ Xu, S Chubb, A Sen, LW Hertel, GB Grindey and W Plunkett
Department of Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
The new deoxycytidine analogue 2',2'-difluorodeoxycytidine (dFdC) is a specific inhibitor of DNA synthesis that has marked cytotoxicity and therapeutic activity. A 2-hr incubation with 0.1-10 microM dFdC decreased cellular viability 78-97%. This treatment reduced deoxynucleoside triphosphate pools, similar to the action of the ribonucleotide reductase inhibitor hydroxyurea. The most pronounced decrease occurred in the dCTP pool, quantitatively followed by the decrease of dATP, dGTP, and dTTP. In contrast, inhibition of DNA synthesis by arabinosylcytosine did not affect the dCTP level, whereas dATP, dGTP, and dTTP pools increased, but less than 2-fold. The incorporation of [5-3H]cytidine into the dCTP pool, a measure of ribonucleotide reductase activity in whole cells, was reduced to 3% of controls by 0.1 microM dFdC, but to only 40% by 0.1 microM ara-C. Each drug decreased incorporation of [5-3H]cytidine into DNA to a similar extent (greater than 94%), suggesting limitation by a reaction proximal to this step. The cellular concentration of dFdC 5'-diphosphate was 0.3 microM at 50% inhibition of the in situ activity of ribonucleotide reductase. Direct assays of partially purified ribonucleoside diphosphate reductase (EC 1.17.4.1) demonstrated 50% inhibition by 4 microM dFdC 5'-diphosphate; dFdC 5'-triphosphate was much less inhibitory. We conclude that dFdC 5'-diphosphate acts as an inhibitor of ribonucleoside diphosphate reductase.
This article has been cited by other articles:
|
|
 |
|
  L. Li, B. Fridley, K. Kalari, G. Jenkins, A. Batzler, S. Safgren, M. Hildebrandt, M. Ames, D. Schaid, and L. Wang Gemcitabine and Cytosine Arabinoside Cytotoxicity: Association with Lymphoblastoid Cell Expression Cancer Res., September 1, 2008; 68(17): 7050 - 7058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sigmond, R. J. Honeywell, T. J. Postma, C. M. F. Dirven, S. M. de Lange, K. van der Born, A. C. Laan, J. C. A. Baayen, C. J. Van Groeningen, A. M. Bergman, et al. Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer Ann. Onc., August 12, 2008; (2008) mdn543v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Veltkamp, D. Pluim, M. A.J. van Eijndhoven, M. J. Bolijn, F. H.G. Ong, R. Govindarajan, J. D. Unadkat, J. H. Beijnen, and J. H.M. Schellens New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine Mol. Cancer Ther., August 1, 2008; 7(8): 2415 - 2425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Veltkamp, R. S. Jansen, S. Callies, D. Pluim, C. M. Visseren-Grul, H. Rosing, S. Kloeker-Rhoades, V. A.M. Andre, J. H. Beijnen, C. A. Slapak, et al. Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study Clin. Cancer Res., June 1, 2008; 14(11): 3477 - 3486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Veltkamp, J. H. Beijnen, and J. H.M. Schellens Prolonged Versus Standard Gemcitabine Infusion: Translation of Molecular Pharmacology to New Treatment Strategy Oncologist, March 1, 2008; 13(3): 261 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yeo, J Kintner, R Armand, R Perez, and L. Lewis Sublethal concentrations of gemcitabine (2',2'-difluorodeoxycytidine) alter mitochondrial ultrastructure and function without reducing mitochondrial DNA content in BxPC-3 human pancreatic carcinoma cells Human and Experimental Toxicology, December 1, 2007; 26(12): 911 - 921. [Abstract] [PDF]
|
|
|
|
 |
|
 D. S. Shewach and T. S. Lawrence Antimetabolite Radiosensitizers J. Clin. Oncol., September 10, 2007; 25(26): 4043 - 4050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wang, G. J. S. Lohman, and J. Stubbe Enhanced subunit interactions with gemcitabine-5'-diphosphate inhibit ribonucleotide reductases PNAS, September 4, 2007; 104(36): 14324 - 14329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Tooker, W.-C. Yen, S.-C. Ng, A. Negro-Vilar, and T. W. Hermann Bexarotene (LGD1069, Targretin), a Selective Retinoid X Receptor Agonist, Prevents and Reverses Gemcitabine Resistance in NSCLC Cells by Modulating Gene Amplification Cancer Res., May 1, 2007; 67(9): 4425 - 4433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Santini, V Virzi, B Vincenzi, L Rocci, V Leoni, and G Tonini A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients Ann. Onc., March 1, 2007; 18(3): 576 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Sugiyama, N. Kaniwa, S.-R. Kim, R. Kikura-Hanajiri, R. Hasegawa, K. Maekawa, Y. Saito, S. Ozawa, J.-i. Sawada, N. Kamatani, et al. Pharmacokinetics of Gemcitabine in Japanese Cancer Patients: The Impact of a Cytidine Deaminase Polymorphism J. Clin. Oncol., January 1, 2007; 25(1): 32 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. F. S. A. Cerqueira, P. A. Fernandes, L. A. Eriksson, and M. J. Ramos Dehydration of Ribonucleotides Catalyzed by Ribonucleotide Reductase: The Role of the Enzyme Biophys. J., March 15, 2006; 90(6): 2109 - 2119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Chung, B. Zhou, X. Liu, L. Zhu, L. M. Boo, H.-V. Nguyen, D. K. Ann, J. Song, Y. Chen, and Y. Yen SUMOylation plays a role in gemcitabine- and bortezomib-induced cytotoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone. Mol. Cancer Ther., March 1, 2006; 5(3): 533 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Kalinowski and D. R. Richardson The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer Pharmacol. Rev., December 1, 2005; 57(4): 547 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Bergman, P. P. Eijk, V. W.T. Ruiz van Haperen, K. Smid, G. Veerman, I. Hubeek, P. van den IJssel, B. Ylstra, and G. J. Peters In vivo Induction of Resistance to Gemcitabine Results in Increased Expression of Ribonucleotide Reductase Subunit M1 as the Major Determinant Cancer Res., October 15, 2005; 65(20): 9510 - 9516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Divers, S. A. Spencer, D. Carey, E. M. Busby, M. D. Hyatt, and F. Robert Phase I/IIa Study of Cisplatin and Gemcitabine As Induction Chemotherapy Followed by Concurrent Chemoradiotherapy With Gemcitabine and Paclitaxel for Locally Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., September 20, 2005; 23(27): 6664 - 6673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. P. Jordheim, O. Guittet, M. Lepoivre, C. M. Galmarini, and C. Dumontet Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells Mol. Cancer Ther., August 1, 2005; 4(8): 1268 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yonemori, H. Ueno, T. Okusaka, N. Yamamoto, M. Ikeda, N. Saijo, T. Yoshida, H. Ishii, J. Furuse, E. Sugiyama, et al. Severe Drug Toxicity Associated with a Single-Nucleotide Polymorphism of the Cytidine Deaminase Gene in a Japanese Cancer Patient Treated with Gemcitabine plus Cisplatin Clin. Cancer Res., April 1, 2005; 11(7): 2620 - 2624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Huxham, A. H. Kyle, J. H. E. Baker, L. K. Nykilchuk, and A. I. Minchinton Microregional Effects of Gemcitabine in HCT-116 Xenografts Cancer Res., September 15, 2004; 64(18): 6537 - 6541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. P. Jordheim, E. Cros, M.-H. Gouy, C. M. Galmarini, S. Peyrottes, J. Mackey, C. Perigaud, and C. Dumontet Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line: Reversion of In vitro Resistance by a Mononucleotide Prodrug Clin. Cancer Res., August 15, 2004; 10(16): 5614 - 5621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Kent, H. Sandler, J. Montie, C. Lee, J. Herman, P. Esper, J. Fardig, and D. C. Smith Combined-Modality Therapy With Gemcitabine and Radiotherapy As a Bladder Preservation Strategy: Results of a Phase I Trial J. Clin. Oncol., July 1, 2004; 22(13): 2540 - 2545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Davidson, L. Ma, M. Flagella, S. Geeganage, L. M. Gelbert, and C. A. Slapak An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines Cancer Res., June 1, 2004; 64(11): 3761 - 3766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Bepler, S. Sharma, A. Cantor, A. Gautam, E. Haura, G. Simon, A. Sharma, E. Sommers, and L. Robinson RRM1 and PTEN As Prognostic Parameters for Overall and Disease-Free Survival in Patients With Non-Small-Cell Lung Cancer J. Clin. Oncol., May 15, 2004; 22(10): 1878 - 1885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wadler, D. Makower, C. Clairmont, P. Lambert, K. Fehn, and M. Sznol Phase I and Pharmacokinetic Study of the Ribonucleotide Reductase Inhibitor, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, Administered by 96-Hour Intravenous Continuous Infusion J. Clin. Oncol., May 1, 2004; 22(9): 1553 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Goel, A. Bulgaru, H. Hochster, S. Wadler, W. Zamboni, M. Egorin, P. Ivy, L. Leibes, F. Muggia, G. Lockwood, et al. Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors Ann. Onc., November 1, 2003; 14(11): 1682 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tempero, W. Plunkett, V. Ruiz van Haperen, J. Hainsworth, H. Hochster, R. Lenzi, and J. Abbruzzese Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma J. Clin. Oncol., September 15, 2003; 21(18): 3402 - 3408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Murren, M. Modiano, C. Clairmont, P. Lambert, N. Savaraj, T. Doyle, and M. Sznol Phase I and Pharmacokinetic Study of Triapine, a Potent Ribonucleotide Reductase Inhibitor, Administered Daily for Five Days in Patients with Advanced Solid Tumors Clin. Cancer Res., September 15, 2003; 9(11): 4092 - 4100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tiefenthaler, F. Hohla, E. Strasser-Wozak, N. Bacher, O. Muhlmann, W. Wein, and G. Konwalinka Delayed Addition of Deoxycytidine Protects Normal CD34+ Cells against Cytotoxicity of Gemcitabine without Compromising Its Activity against Human Leukemic Cells Stem Cells, May 1, 2003; 21(3): 266 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Moufarij, D. R. Phillips, and C. Cullinane Gemcitabine Potentiates Cisplatin Cytotoxicity and Inhibits Repair of Cisplatin-DNA Damage in Ovarian Cancer Cell Lines Mol. Pharmacol., April 1, 2003; 63(4): 862 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mavroudis, P. Pappas, C. Kouroussis, S. Kakolyris, S. Agelaki, K. Kalbakis, N. Androulakis, J. Souglakos, N. Vardakis, M. Nikolaidou, et al. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors Ann. Onc., February 1, 2003; 14(2): 304 - 312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Hensley, R. Maki, E. Venkatraman, G. Geller, M. Lovegren, C. Aghajanian, P. Sabbatini, W. Tong, R. Barakat, and D. R. Spriggs Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial J. Clin. Oncol., June 15, 2002; 20(12): 2824 - 2831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Gandhi, W. Plunkett, M. Du, M. Ayres, and E. H. Estey Prolonged Infusion of Gemcitabine: Clinical and Pharmacodynamic Studies During a Phase I Trial in Relapsed Acute Myelogenous Leukemia J. Clin. Oncol., February 1, 2002; 20(3): 665 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Schilsky, D. Bertucci, N. J. Vogelzang, H. L. Kindler, and M. J. Ratain Dose-Escalating Study of Capecitabine Plus Gemcitabine Combination Therapy in Patients With Advanced Cancer J. Clin. Oncol., January 15, 2002; 20(2): 582 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Blackstock, H. Lightfoot, L. D. Case, J. E. Tepper, S. K. Mukherji, B. S. Mitchell, S. G. Swarts, and S. M. Hess Tumor Uptake and Elimination of 2',2'-Difluoro-2'-deoxycytidine (Gemcitabine) after Deoxycytidine Kinase Gene Transfer: Correlation with in Vivo Tumor Response Clin. Cancer Res., October 1, 2001; 7(10): 3263 - 3268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Patel, V. Gandhi, J. Jenkins, N. Papadopolous, M. A. Burgess, C. Plager, W. Plunkett, and R. S. Benjamin Phase II Clinical Investigation of Gemcitabine in Advanced Soft Tissue Sarcomas and Window Evaluation of Dose Rate on Gemcitabine Triphosphate Accumulation J. Clin. Oncol., August 1, 2001; 19(15): 3483 - 3489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Eisbruch, D. S. Shewach, C. R. Bradford, J. F. Littles, T. N. Teknos, D. B. Chepeha, L. J. Marentette, J. E. Terrell, N. D. Hogikyan, L. A. Dawson, et al. Radiation Concurrent With Gemcitabine for Locally Advanced Head and Neck Cancer: A Phase I Trial and Intracellular Drug Incorporation Study J. Clin. Oncol., February 1, 2001; 19(3): 792 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Ostruszka and D. S. Shewach The Role of Cell Cycle Progression in Radiosensitization by 2',2'-Difluoro-2'-deoxycytidine Cancer Res., November 1, 2000; 60(21): 6080 - 6088. [Abstract] [Full Text]
|
|
|
|
|
|
A. P. Venook, M. J. Egorin, G. L. Rosner, D. Hollis, S. Mani, M. Hawkins, J. Byrd, R. Hohl, D. Budman, N. J. Meropol, et al. Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565 J. Clin. Oncol., July 14, 2000; 18(14): 2780 - 2787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. I. Rini, N. J. Vogelzang, M. C. Dumas, J. L. Wade III, D. A. Taber, and W. M. Stadler Phase II Trial of Weekly Intravenous Gemcitabine With Continuous Infusion Fluorouracil in Patients With Metastatic Renal Cell Cancer J. Clin. Oncol., June 12, 2000; 18(12): 2419 - 2426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Coucke, L. A. Decosterd, Y.-X. Li, E. Cottin, X. Chen, L.-Q. Sun, S. Stern, N. Paschoud, and J. Denekamp The Ribonucleoside Diphosphate Reductase Inhibitor (E)-2'-Deoxy-(fluoromethylene)cytidine as a Cytotoxic Radiosensitizer in Vitro Cancer Res., October 1, 1999; 59(20): 5219 - 5226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. B. Parker, S. C. Shaddix, L. M. Rose, D. S. Shewach, L. W. Hertel, J. A. Secrist III, J. A. Montgomery, and L. L. Bennett Jr. Comparison of the Mechanism of Cytotoxicity of 2-Chloro-9-(2-deoxy-2-fluoro-beta -D-arabinofuranosyl)adenine, 2-Chloro-9-(2-deoxy-2-fluoro-beta -D-ribofuranosyl)adenine, and 2-Chloro-9-(2-deoxy-2,2-difluoro-beta -D-ribofuranosyl)adenine in CEM Cells Mol. Pharmacol., March 1, 1999; 55(3): 515 - 520. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Kramata, K. M. Downey, and L. R. Paborsky Incorporation and Excision of 9-(2-Phosphonylmethoxyethyl)guanine (PMEG) by DNA Polymerase delta and epsilon in Vitro J. Biol. Chem., August 21, 1998; 273(34): 21966 - 21971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Iwasaki, P. Huang, M. J. Keating, and W. Plunkett Differential Incorporation of Ara-C, Gemcitabine, and Fludarabine Into Replicating and Repairing DNA in Proliferating Human Leukemia Cells Blood, July 1, 1997; 90(1): 270 - 278. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
